LETTER TO THE EDITOR
Bcl-2 protein in diffuse large B-cell lymphoma
Proteína Bcl-2 em linfoma difuso de grandes células B
Viroj Wiwanitkit
MD, PhD. Professor, Wiwanitkit House, Bangkhae, Bangkok, Thailand
Address for correspondence Address for correspondence: Professor Viroj Wiwanitkit Wiwanitkit House, Bangkhae, Bangkok Thailand 10160 Tel. (+66) 241324436 E- mail: wviroj@yahoo.com
Dear Editor,
I read the recently published paper on Bcl-2 with great interest. 1 Hallack Neto et al. concluded that "Bcl-2 protein was expressed in 37% of the high-risk DLBCL patients, without any difference between the ABC-like DLBCL and GCB-like DLBCL cases. 1" Indeed, the clinical value of determining Bcl-2 in B-cell lymphoma is still controversial. However, there are some problems in this work. The retrospective cohort design is not a common approach. There is also no risk classification from the analysis. The small number of subjects in this work might not be statistically acceptable for any conclusion.
Date of first submission: June 18, 2010
Last received: June 18, 2010
Accepted: November 3, 2010
Sources of funding: None
Conflict of interest: None
-
1Hallack Neto AE, Siqueira SA, Dulley FL, et al. Bcl-2 protein frequency in patients with high-risk diffuse large B-cell lymphoma. São Paulo Med J. 2010;128(1):14-7.
Publication Dates
-
Publication in this collection
10 Mar 2011 -
Date of issue
Jan 2011